Trillium Therapeutics Inc. (TRIL) Stock Rating Lowered by Zacks Investment Research
Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.
According to Zacks, “Trillium Therapeutics Inc. is an immuno-oncology company. It engages in developing therapies for the treatment of cancer. The Company has two premier preclinical programs, SIRP?Fc and a CD200 monoclonal antibody, which target two key immunoregulatory spathway that tumor cells exploit to evade the host immune system. Trillium Therapeutics Inc. is based in Canada. “
Several other brokerages have also recently issued reports on TRIL. Ladenburg Thalmann started coverage on shares of Trillium Therapeutics in a research note on Wednesday, August 3rd. They set a “buy” rating and a $18.00 target price on the stock. BTIG Research started coverage on shares of Trillium Therapeutics in a research note on Thursday, October 6th. They set a “buy” rating and a $21.00 target price on the stock. Cowen and Company reaffirmed a “buy” rating on shares of Trillium Therapeutics in a research note on Thursday, November 3rd. Bloom Burton reaffirmed a “buy” rating on shares of Trillium Therapeutics in a research note on Friday, November 4th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $20.00 target price on shares of Trillium Therapeutics in a research note on Monday, August 15th. Seven research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus price target of $21.15.
Trillium Therapeutics (NASDAQ:TRIL) opened at 8.75 on Tuesday. Trillium Therapeutics has a 1-year low of $6.62 and a 1-year high of $17.70. The company has a 50-day moving average of $12.94 and a 200 day moving average of $11.41. The stock’s market cap is $68.37 million.
Several hedge funds and other institutional investors have recently made changes to their positions in TRIL. Creative Planning boosted its position in shares of Trillium Therapeutics by 37.3% in the third quarter. Creative Planning now owns 8,100 shares of the company’s stock valued at $120,000 after buying an additional 2,200 shares during the last quarter. Schonfeld Strategic Advisors LLC bought a new position in Trillium Therapeutics during the first quarter worth approximately $100,000. Wells Fargo & Company MN boosted its position in Trillium Therapeutics by 1,080.0% in the third quarter. Wells Fargo & Company MN now owns 11,800 shares of the company’s stock worth $175,000 after buying an additional 10,800 shares during the last quarter. K2 Principal Fund L.P. bought a new position in Trillium Therapeutics during the second quarter worth approximately $131,000. Finally, Susquehanna International Group LLP bought a new position in Trillium Therapeutics during the third quarter worth approximately $372,000. 41.39% of the stock is currently owned by hedge funds and other institutional investors.
Receive News & Stock Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related stocks with our FREE daily email newsletter.